The bispecific antibody therapeutics pipeline has evolved significantly over the past few years, claims Roots Analysis

With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

Advertisements
WP Rocket - WordPress Caching Plugin

 

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link

 

The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:

  • Therapeutic Area
  • Autoimmune Disorders
  • Eye Disorders
  • Genetic Disorders
  • Hematological Malignancies
  • Infectious Diseases
  • Inflammatory Disorders
  • Skin Disorders
  • Mechanism of Action
  • Cytokines Retargeting / Neutralization
  • Dual Ligands Blocking
  • T-cell Retargeting / Activation
  • Other
  • Target Antigens
  • CD3 x CD19
  • CD30 x CD16A
  • Factor IXa x Factor X
  • IL-1α x IL-1β
  • IL-13 x IL-4
  • IL-17A x Albumin
  • IL-17A x IL-17F
  • Psl x PcrV
  • VEGF-A x ANG2
  • Others
  • Antibody Formats
  • Asymmetric
  • Fragments
  • Symmetric
  • Others

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific

 

The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Amgen
  • Ablynx
  • AbbVie
  • Affibody
  • Affimed
  • Alphamab
  • AstraZeneca
  • Avillion
  • Chugai Pharmaceuticals
  • Eddingpharm
  • GSK
  • Merck
  • Merus
  • Roche
  • Regeneron Pharmaceuticals
  • Taisho Pharmaceuticals
  • Zymeworks

Table of Contents

  1. Preface
    2. Executive Summary
  2. Introduction
  3. Market Overview
  4. Bispecific Antibody Therapeutics: Technology Platforms
  5. Drug Profiles
  6. Key Insights
  7. Benchmark Analysis: Big Pharma Players
  8. Partnerships and Collaborations
  9. Contract Services for Bispecific Antibody Therapeutics
  10. Clinical Trial Analysis
  11. Case Study: Regulatory Guidelines for Bispecific Antibodies
  12. Case Study: Promotional / Marketing Strategies
  13. SWOT Analysis
  14. Market Forecast and Opportunity Analysis
  15. Concluding Remarks
  16. Executive Insights
  1. Appendix 1: Tabulated Data
  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com